Exciting Milestone for PharmNovo!
Published
by
PharmNovo has received positive and constructive feedback from the FDA for its lead drug candidate, PN6047, a selective delta opioid receptor agonist aimed at treating peripheral neuropathy with allodynia.
Per von Mentzer, CEO: “In contrast to most pre-IND meetings where FDA provides written response only, FDA granted PharmNovo a meeting. We take this as an indication of great interest in PN6047 and we are grateful for the support and guidance FDA has provided PharmNovo and our plans for development of PN6047 for neuropathic pain“.
Read the full press release here:
Follow us: